CSS
MLTX icon

Cubist Systematic Strategies’s MoonLake Immunotherapeutics MLTX Stock Holding History

Cubist Systematic Strategies’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$243K Sell
33,878
-4,326
-11% -$225K ﹤0.01% 2594
2025
Q2 		$1.8M Buy
38,204
+13,385
+54% +$545K 0.01% 1607
2025
Q1 		$970K Buy
+24,819
New +$1.07M 0.01% 1837
2023
Q2 		– Sell
-59,858
Closed -$1.28M – 3996
2023
Q1 		$1.28M Buy
+59,858
New +$1.01M 0.01% 1985

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cubist Systematic Strategies's MLTX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its MoonLake Immunotherapeutics (MLTX) stake by 11% in Q3 2025, selling an estimated $225K and leaving 33,878 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #2594.

Cubist Systematic Strategies first reported a position in MLTX in Q1 2023 and has held it in 4 quarters since. The position peaked at $1.8M in Q2 2025. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Cubist Systematic Strategies held 33,878 shares of MoonLake Immunotherapeutics worth $243K as of Q3 2025.
  • Cubist Systematic Strategies sold 4,326 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $225K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2594 holding.
  • Cubist Systematic Strategies first reported a position in MoonLake Immunotherapeutics in Q1 2023 and has held it in 4 quarters since.
  • Cubist Systematic Strategies's MoonLake Immunotherapeutics position peaked at $1.8M in Q2 2025.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.